Ko YH, Lee MA, Hong YS, Lee KS, Park HJ, Yoo IR, Kim YS, Kim YK, Jo KH, Wang YP, Lee KY, Kang JH
BACKGROUND: Second-line chemotherapy offers advanced non-small cell lung cancer (NSCLC) patients a small, but significant increase in survival. Docetaxel is usually administered as a 3-week schedule, yet there is...